Canterbury Care

Labiotech.eu | January 27, 2020

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

TheDailyTimes | April 15, 2020

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

CELL AND GENE THERAPY

Exact Sciences Corporation | January 10, 2022

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

INDUSTRIAL IMPACT

InnoRNA and BeiGene | July 07, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...